Response to Letter Regarding Article, "Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial"

被引：0

作者：

Shahbaznejad, Leila ^{[1
]}

Davoudi, Alireza ^{[2
]}

Eslami, Gohar ^{[3
]}

Markowitz, John S. ^{[4
]}

Navaeifar, Mohammad Reza ^{[1
]}

Hosseinzadeh, Fatemeh ^{[1
]}

Movahedi, Faeze Sadat ^{[5
]}

Rezai, Mohammad Sadegh ^{[1
]}

机构：

[1] Mazandaran Univ Med Sci, Communicable Dis Inst, Pediat Infect Dis Res Ctr, Sari, Iran

[2] Mazandaran Univ Med Sci, Communicable Dis Inst, Dept Infect Dis, Antimicrobial Resistance Res Ctr, Sari, Iran

[3] Mazandaran Univ Med Sci, Cardiovasc Res Ctr, Fac Pharm, Dept Clin Pharm, Sari, Iran

[4] Univ Florida, Ctr Pharmacogen & Precis Med, Dept Pharmacotherapy & Translat Res, Gainesville, FL USA

[5] Mazandaran Univ Med Sci, Student Res Comm, Sari, Iran

来源：

CLINICAL THERAPEUTICS | 2021年 / 43卷 / 09期

关键词：

D O I：

10.1016/j.clinthera.2021.07.006

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

下载

页码：1624 / 1626

页数：3

共 50 条

[1] Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical Trial
Shahbaznejad, Leila
Davoudi, Alireza
Eslami, Gohar
Markowitz, John S.
Navaeifar, Mohammad Reza
Hosseinzadeh, Fatemeh
Movahedi, Faeze Sadat
Rezai, Mohammad Sadegh
CLINICAL THERAPEUTICS, 2021, 43 (06) : 1007 - 1019
[2] Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients
Ulrich, Robert J.
Troxel, Andrea B.
Carmody, Ellie
Eapen, Jaishvi
Backer, Martin
DeHovitz, Jack A.
Prasad, Prithiv J.
Li, Yi
Delgado, Camila
Jrada, Morris
Robbins, Gabriel A.
Henderson, Brooklyn
Hrycko, Alexander
Delpachitra, Dinuli
Raabe, Vanessa
Austrian, Jonathan S.
Dubrovskaya, Yanina
Mulligan, Mark J.
OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (10):
[3] Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial
Julio Vallejos
Rodrigo Zoni
María Bangher
Silvina Villamandos
Angelina Bobadilla
Fabian Plano
Claudia Campias
Evangelina Chaparro Campias
Maria Fernanda Medina
Fernando Achinelli
Hector Andres Guglielmone
Jorge Ojeda
Diego Farizano Salazar
Gerardo Andino
Pablo Kawerin
Silvana Dellamea
Antonia Cristina Aquino
Victor Flores
Carolina N. Martemucci
Silvina Maria Martinez
Juan Emanuel Segovia
Paola Itati Reynoso
Noelia Carolina Sosa
Mariana Elizabeth Robledo
Joaquina Maria Guarrochena
Maria Mercedes Vernengo
Natalia Ruiz Diaz
Elba Meza
María Gabriela Aguirre
BMC Infectious Diseases, 21
[4] Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial
Vallejos, Julio
Zoni, Rodrigo
Bangher, Maria
Villamandos, Silvina
Bobadilla, Angelina
Plano, Fabian
Campias, Claudia
Chaparro Campias, Evangelina
Fernanda Medina, Maria
Achinelli, Fernando
Andres Guglielmone, Hector
Ojeda, Jorge
Farizano Salazar, Diego
Andino, Gerardo
Kawerin, Pablo
Dellamea, Silvana
Cristina Aquino, Antonia
Flores, Victor
Martemucci, Carolina N.
Maria Martinez, Silvina
Emanuel Segovia, Juan
Itati Reynoso, Paola
Carolina Sosa, Noelia
Elizabeth Robledo, Mariana
Maria Guarrochena, Joaquina
Mercedes Vernengo, Maria
Ruiz Diaz, Natalia
Meza, Elba
Gabriela Aguirre, Maria
BMC INFECTIOUS DISEASES, 2021, 21 (01)
[5] The effects of colchicine on hospitalized COVID-19 patients: A randomized, double-blind, placebo-controlled clinical trial
Kasiri, Hossein
Ghazaiean, Mobin
Rouhani, Nima
Naderi-behdani, Fahimeh
Ghazaeian, Monireh
Ghodssi-Ghassemabadi, Robabeh
JOURNAL OF INVESTIGATIVE MEDICINE, 2023, 71 (02) : 124 - 131
[6] Efficacy and safety of oral ivermectin in the treatment of mild to moderate Covid-19 patients: a multi-centre double-blind randomized controlled clinical trial
Wijewickrema, Ananda
Banneheke, Hasini
Pathmeswaran, Arunasalam
Refai, Fathima Wardha
Kauranaratne, Malika
Malavige, Neelika
Jeewandara, Chandima
Ekanayake, Mahendra
Samaraweera, Dilhar
Thambavita, Dhanusha
Galappatthy, Priyadarshani
BMC INFECTIOUS DISEASES, 2024, 24 (01)
[7] Effect of pioglitazone on inflammatory response and clinical outcome in T2DM patients with COVID-19: a randomized multicenter double-blind clinical trial
Baagar, Khaled
Alessa, Thamer
Abu-Farha, Mohamed
Abubaker, Jehad
Alhumaidi, Heba
Ceruto, Jose Antonio Franco
Hamad, Mohammad Khair
Omrani, Ali
Abdelrahman, Salma
Zaka-Ul Haq, Muhammad
Safi, Abdul Wajid
Alhariri, Bassem
Barman, Manish
Abdelmajid, Alaaeldin
Cancio, Humberto Vidal Denis
Elmekaty, Eman
Al-Khairi, Irina
Cherian, Preethi
Jayyousi, Lina
Ahmed, Mohammed
Qaddoumi, Mohammed
Hajji, Sulaiman
Esmaeel, Ahmad
Al-Andaleeb, Ali
Channanath, Arshad
Devarajan, Sriraman
Ali, Hamad
Thanaraj, Thangavel Alphonse
Al-Sabah, Salman
Al-Mulla, Fahd
Abdul-Ghani, Muhammad
Jayyousi, Amin
FRONTIERS IN IMMUNOLOGY, 2024, 15
[8] Ludangshen oral liquid for treatment of convalescent COVID-19 patients: a randomized, double-blind, placebo-controlled multicenter trial
Xuedong An
Bo Peng
Xiaodong Huang
Hongmei Jiang
Zhang’e Xiong
Hong Zhang
Fengmei Lian
Yuanming Ba
Xiaolin Tong
Chinese Medicine, 17
[9] Ludangshen oral liquid for treatment of convalescent COVID-19 patients: a randomized, double-blind, placebo-controlled multicenter trial
An, Xuedong
Peng, Bo
Huang, Xiaodong
Jiang, Hongmei
Xiong, Zhang'e
Zhang, Hong
Lian, Fengmei
Ba, Yuanming
Tong, Xiaolin
CHINESE MEDICINE, 2022, 17 (01)
[10] Pentoxifylline effects on hospitalized patients with COVID19: A randomized, double-blind clinical trial
Azizi, Hanieh
Rouhani, Nima
Shaki, Fatemeh
Karimpour-razkenari, Elahe
Ghazaeian, Monireh
Salehifar, Ebrahim
Saeedi, Majid
Fallah, Sahar
INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 101

← 1 2 3 4 5 →